It is proposed that future NLRP3-targeted therapy for osteomyelitis should shift from “non-specific anti-inflammation” to “bone immune reprogramming”—stratified intervention based on infection stage, cell type, and inflammasome activation level, integrating NLRP3 modulation with antibacterial, anti-biofilm, anti-pyropt...
Li-Dan Yang, Lin Zhang, Xu-Xu Yang et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.